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Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and
it is one of the leading causes of cancer-related deaths worldwide. The global burden of
hepatocellular carcinoma is growing nowadays. Most cases of hepatocellular carcinoma
develop in the background of chronic hepatitis C and B and liver cirrhosis‑well-known
risk factor. But despite the reducing incidence of chronic hepatitis infections, an increase in
the incidence of hepatocellular carcinoma was observed in the last decades. This could be
explained by the increasing prevalence of obesity, type 2 diabetes mellitus, nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), which are becom-
ing important risk factors in hepatocellular carcinoma. Regular surveillance, as performed
for patients with viral hepatitis, is required for patients with metabolic risk factors.
Keywords: hepatocellular carcinoma, nonalcoholic fatty liver disease, nonalcoholic
steatohepatitis
1. Introduction
Hepatocellular carcinoma (HCC) is one of the dominant histopathological types of liver cancer,
accounting for almost 90% of primary liver cancers worldwide, it is the sixth most common
cancer and it is the third cause of cancer-related deaths worldwide [1]. Despite the decreasing
incidence of HCC related to viral hepatitis, an increase in the incidence of HCC was observed
especially in Europe and America [2]. The global burden of hepatocellular carcinoma in 2012
was of 14 million cases and it is predicted to grow to 22 million over the next two decades.
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The most common and known risk factor for HCC are viral infection, virus B or C, toxic factors
- alcohol and aflatoxin and immune diseases like primary biliary cirrhosis. There is an increas-
ing number of HCC developed on liver metabolic diseases, including NAFLD and NASH,
based on epidemiological evidence that shows a relationship of these diseases with an incident
of HCC, regardless of the common known risk factors like alcohol consumption or chronic
viral hepatitis.
It is not surprising the growing interest in the last few years on the mechanisms underlying the
transition from liver metabolic disorders to HCC that is involving these new metabolic risk
factors that include inflammation, insulin resistance, lipid and bile acids metabolism and the
gut microbiota. A better understanding of the impact of these factors on the liver microenvi-
ronment may have potential benefit on the management of liver disease [3].
Metabolic syndrome has been associated with an increased risk of HCC and each component
of this syndrome may increase cancer risk and also a synergic effect has been described [4, 5].
Overweight and obesity are well recognized independent risk factors for HCC, visceral adi-
posity showing stronger association with HCC risk than general body weight [6, 7]. Studies
demonstrated that obesity may also influence HCC prognosis, Body Mass Index (BMI) seems
to be a predictor of microvascular invasion and poor prognosis, while visceral adiposity is
associated with HCC recurrence after treatment [8, 9]. Type 2 diabetes mellitus has been
recognized in various studies as an important independent risk factor for HCC regardless of
alcohol consumption [10]. Hyperlipidemia and hypertension are two additional components
of metabolic syndrome that have been studied as risk factors for HCC, and hypertension seems
to be related to a higher risk of HCC, whereas the relation between HCC and hyperlipidemia
remains controversial [4, 5]. Also, synergism between the new risk factors and traditional risk
factors has to be considered, for example, a strong synergic effect of alcohol abuse and type 2
diabetes mellitus has been described, also diabetes and obesity have been reported to enhance
the risk of HCC in patients with chronic hepatitis [11, 12].
Non alcoholic fatty liver disease (NAFLD) is one of the most common cause of chronic liver
disease and include a large spectrum of chronic liver disorders ranging from simple hepatic
steatosis with no evidence of hepatocellular injury to non-alcoholic steatohepatitis (NASH),
advanced fibrosis, cirrhosis and liver failure and currently, all guidelines agree that NAFLD is
associated with the increasing percentage of obesity, type 2 diabetes mellitus, hypertension
and dyslipidemia in our population [13, 14]. Several studies have demonstrated a strong
association between NAFLD and each components of metabolic syndrome and there is enough
evidence to define NAFLD itself as a liver component of metabolic syndrome [1519, 46].
The rising incidence of NAFLD/NASH worldwide led to an important rise in HCC incidence
related to these chronic liver diseases [3]. Many studies have demonstrated over the years that
NAFLD can lead to hepatic fibrosis and cirrhosis, increasing therefore the risk for developing
HCC [20, 21]. Among these patients with Non alcoholic fatty liver disease or non-alcoholic
steatohepatitis, studies show that the third cause of death is liver disease, and HCC represents
the main cause of death in these patients [2023]. The incidence rate for developing HCC in
patients with NASH related hepatic cirrhosis is up to 27% in retrospective studies [24].
Increased incidence of HCC was also been reported in patients with NAFLD in the absence of
hepatic cirrhosis, and several risk factors for HCC development have been identified [6, 2529].
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2. Natural history: Progression from hepatic steatosis to HCC
The term nonalcoholic fatty liver refers to a variety of liver disease that ranges from simple
isolated hepatic steatosis, to non-alcoholic steatohepatitis with or without cirrhosis, and pro-
gression to HCC.
Although NAFLD diagnosis can be made by imaging (ultrasound or magnetic resonance),
biopsy still remain the gold standard for diagnosis. Histology generally displays the accumu-
lation of triglycerides in hepatocytes, usually in mixed macrovesicular or microvesicular drop-
lets, in the absence of alcohol abuse, steatogenic medication or hereditary disorders [30].
The prevalence of NASH is difficult to determine because biopsy is required, with specific
criteria such as steatosis, hepatocellular injury, mainly in the form of ballooning, and lobular
inflammation, and once cirrhosis is present, NASH may be difficult to evaluate because often
the fatty deposition disappear. Liver fibrosis may be present in non-cirrhotic NASH, initially in
perisinusoidal acinar zone 3 [31]. Because of the need of histopathologic confirmation, NASH
is most likely underdiagnosed and it may be misclassified as cryptogenic cirrhosis, which
shares the same risk factors including diabetes and obesity [32, 33, 46]. Therefore, to estimate
correctly the prevalence of NASH, a novel NASH category including obese patients with
cryptogenic cirrhosis or with unknown HCC etiology has been proposed.
The prevalence of NAFLD and NASH is variable and it is depended on the method of
diagnostic used to confirm the disease, and it is usually underreported because of the asymp-
tomatic nature and can be underestimated and poorly treated.
NAFLD is present in more than 25% of adult population and about 10 to 20% of NAFLD
patients may progress to NASH, which may progress to cirrhosis in 2045% of cases, and
cirrhosis is a well-known risk factor for HCC, and approximately 7% of patients with NASH-
related cirrhosis may progress to HCC within 6 years [31].
Patients with nonalcoholic steatohepatitis are more susceptible to develop progressive advanced
liver disease when compared to benign course of simple hepatic steatosis. In a study that
included 420 patients with NAFLD/NASH, it was demonstrated a higher mortality in these
patients when compared to the general population and also liver-related deaths occurred in
13% compared to 1% in general population, and 3% of patients with NAFLD developed hepatic
cirrhosis. [34] Another study showed increased rates of hepatic cirrhosis in patients with non-
alcoholic steatohepatitis (25%) compared to patients with fatty liver without non-alcoholic
steatohepatitis (3%), and also showed an increased risk of liver disease related death in these
patients (11% vs 2% in patients with fatty liver without NASH) [35].
Patients with compensated liver cirrhosis related to non-alcoholic steatohepatitis present with
better survival outcomes compared to patients with HCV related cirrhosis, but in the presence of
uncompensated liver cirrhosis poor prognosis was observed in both populations [36, 37], and
currently, both, the American and European Associations for the Study of Liver Diseases, recom-
mend screening for HCC in all patients with non-alcoholic steatohepatitis related cirrhosis [38].
Evidence from studies suggests that an important proportion of patients with NAFLD-
associated HCC, do not have histologic evidence of liver cirrhosis. In one study from 1168
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patients that underwent hepatic surgery for HCC, 6 out of 8 patients with NASH-related HCC
did not had any histopathological evidence of liver cirrhosis and also the study suggested that
the presence of hepatic cirrhosis in NASH-related HCC patients is lower compared to HCV-
related HCC [29].
In another study that analyzed 128 patients with HCC recruited over a period of 12 years, it was
reported that a significant number of patients with NASH developed HCC in the absence of
fibrosis when compared to HCC of other etiology [39]. To explain this phenomenon in non-
cirrhotic NAFLD patients, one proposed hypothesis is the malignant transformation of liver cell
adenoma, and there are some published reports that have suggested that in the presence of
metabolic syndrome features, liver cell adenoma may incur a malignant transformation [40, 41].
In the last years, many studies tried to establish the relationship between NAFLD and NASH,
cryptogenic cirrhosis and HCC. The true prevalence of NASH and NASH-related HCC is
probably underestimated due to the asymptomatic nature of the disease, and in up to 29% of
HCC cases, the underlying etiology of liver disease remains unknown or are considered as
cryptogenic cirrhosis [40]. Histopathological features that are suggestive for non-alcoholic
steatohepatitis are more frequently observed in patients with HCC of unknown etiology than
in patients with HCC related to chronic viral hepatitis or alcoholic etiology [32]. Even if the
true prevalence of NAFLD/NASH-related HCC is not yet well defined, the increasing inci-
dence of obesity and diabetes, suggests that the incidence NAFLD/NASH-related HCC will
continue to grow in the next years, and there are already numerous studies that are investi-
gated the relation between these diseases [46].
3. Metabolic risk factors, NAFLD and HCC
It is established that HCC and NAFLD share many risk factors and the development of HCC in
NAFLD/NASH patients is probably multifactorial and involves low grade chronic systemic
inflammatory response, excessive fat accumulation and insulin resistance [40, 46].
3.1. Obesity
There is more evidence that overweight and obesity and metabolic syndrome have reached a
epidemic proportion over the last decades, and there are evident data that show that 80% of
NAFLD patients are overweight or obese [42]. According to the World Health Organization, in
2008, more than 35% of adults worldwide are overweight, and of these, 13% are obese [29] and
if overweight and obesity rates continue at their current ascending trend, it is estimated that
more than 3.3 billion adults will become overweight or obese by year 2030 [43].
Overweight and obesity are leading risk factors for overall mortality, accounting for more than
3.4 million adult deaths every year, and are considered risk factors for 44% of the diabetes, 23%
of the ischemic heart disease, and between 7 and 40% of certain cancer [42].
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Body Mass Index is the most commonly used index in epidemiologic studies, but body fat
topography, and especially central obesity, seems to be more important in pathophysiologic
mechanisms that connect obesity to cancer. Central obesity, is the key feature in most metabolic
syndrome definitions, and has also been directly correlated with insulin resistance [44, 46].
Obesity have been associated with disproportion between visceral and subcutaneous adipose
tissue and with chronic inflammatory state due to adipokine imbalance that is defined as
increased levels of leptin and decreased levels of adiponectin. Furthermore, obesity has been
associated with other risk factors including insulin resistance, increased hepatic lipid storage
and alteration of intestinal flora [46].
Adipokine imbalance as mentioned before occurs with simultaneous increased leptin and
decreased adiponectin levels resulting in a pro-inflammatory and pro-oncogenic state. Both
leptin and adiponectin are hallmarks of obesity, and have been extensively studied and both
have been related to NAFLD and progression to liver cancer.
Leptin is secreted by adipose tissue and acts as a hormone and it is involved in the process of
satiety. High levels of leptin and resistance to its action are observed in obese persons. Leptin
has been demonstrated to be implicated in NAFLD progression, liver fibrosis, NASH and
eventually in the carcinogenesis process of HCC through multiple molecular mechanisms.
And these mechanisms are the activation of JAK2/STAT3, PI-3 K/Akt, ERK pathways and the
inhibition of the TGFβ1-induced apoptotic pathway [24]. For example, the activation of Akt
pathway was observed in about 40% of HCC patients. Leptins role is to have growth factor-
like activities on hepatic cells and HCC cells, and also have proinflammatory, profibrogenic
and proangiogenic role on liver microenvironment and also it is implicated in the process of
cell growth, angiogenesis and metastasis [31].
Adiponectin is the most abundant hormone of adipose tissue and has well known metabolic
functions, having anti-inflammatory, antifibrotic, antiangiogenic, and antiproliferative activi-
ties on the liver microenvironment. Adiponectin exerts antifibrotic effects on hepatic cells
through activation of the signaling AMPK axis and inhibition of TGFβ-mediated profibrogenic
gene expression, and in addition, adiponectin may also induce apoptosis of hepatic cells. The
anti-inflammatory activity of adiponectin is mostly related to inhibition of NFkB signaling axis
[31]. A direct effect of adiponectin on HCC cells has also been described, induces apoptosis
and inhibits HCC cell proliferation and migration. In addition, adiponectin prevents HCC
development by activation of the AMPK signaling pathway and consequent modulation of
mTOR and JNK/caspase 3 axis, resulting in growth cell inhibition and enhanced apoptosis [4].
A number of observations support the reduced adiponectin levels observed in obese patients
and were associated to increased incidence of hepatic steatosis, fibrosis and accelerated pro-
gression to HCC [45].
3.2. Insulin resistance
Insulin resistance it is another important component of the metabolic syndrome, and along
with obesity, is involved in the chronic inflammatory state directly linked to NAFLD. Insulin
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resistance is also related to oxidative stress, which has the most important role in carcinogen-
esis in the presence of NAFLD and NASH.
Epidemiologic studies show that diabetes is associated with an increased risk of developing
HCC compared with non-diabetics patients, regardless of other HCC risk factors and also
seems to be independent of obesity [47]. In a large study conducted on patients with and
without diabetes, with a follow-up period of 1015 years, NAFLD incidence was significantly
higher among patients with diabetes and a significantly higher incidence of HCC among
patients with diabetes was observed [7]. Meta-analysis published over the years, revealed a 2
to 3-fold greater risk of HCC in patients with diabetes compared with non-diabetic patients,
and this significant association was reported independent of alcohol abuse or chronic viral
hepatitis in studies that examined these factors [48, 49].
Epidemiologic data demonstrate that both obesity and type 2 diabetes mellitus have increases
the risk for HCC, and NAFLD, which is present in up to 90% of obese persons and up to 70% of
type 2 diabetes mellitus patients [24], appears to play an important role in HCC development.
NAFLD is nowadays considered the most common risk factor for HCC, followed by type 2
diabetes and it is exceeding the incidence of chronic viral infections and alcoholic liver disease
[48, 50]. These can be explained by effective measures to reduce HCV infection incidence,
which was the major cause of HCC in the United States and in other developed countries,
and also can be explained by the increasing prevalence of NAFLD in these areas [51].
The strong relationship between visceral obesity and insulin resistance (IR) is well known, but
insulin resistance is not related only to adipose tissue, in fact, liver accumulation of fatty acid
metabolites can induce hepatic insulin resistance. One of the main fatty acid metabolite
involved in hepatic insulin resistance is diacylglycerol (DAG) and it has been proposed as a
predictor for hepatic insulin resistance [52]. The consequent hyperinsulinemia downregulates s
expression of IRS2 in the hepatic cells increasing hepatic insulin resistance and in addition,
insulin stimulates lipogenesis through activation of SREBP-1c, inducing, in a vicious circle
with further fat accumulation and insulin resistance [31]. The liver microenvironment may
induce insulin resistance also in other tissues, in fact, an increase in liver fat content may be
considered a very strong predictor of insulin resistance in skeletal muscles, hepatic and adi-
pose tissue, regardless of adiposity. In conclusion, liver fat content may predict the develop-
ment of metabolic syndrome or diabetes, and the underlying mechanism may be the altered
gene expression and protein synthesis and secretion also observed in NAFLD [53]. It is known
that hyperinsulinemia occurs as a response to insulin resistance, and that is considered a risk
factor for liver fibrosis and HCC development by activation of hepatic stellate cells, by
dysregulation in the proliferation-apoptosis balance in hepatic cells, and by stimulation of
angiogenesis. The most studied mechanism involved in NAFLD-related HCC is the IGF sig-
naling axis that has a growth factor-like activity on hepatic cells and also a pro-angiogenic
activity on the hepatic vascular system. Dysregulation of the IGF signaling axis has an impor-
tant role in hepatic carcinogenesis and it is represented by the low levels of IGF1 in serum and
overexpression of IGF-II. Insulin receptors (IRS) bind to insulin or IGF and share the same pro-
oncogenic pathways with IGF1 receptor (IGF1R), including the activation of P13K/Akt and
MAPK [54, 55].
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3.3. Lipotoxicity
Increased lipid accumulation in the liver arises from lipolysis within peripheral adipose tissue,
dietary sources and de novo hepatic lipogenesis, and this increased lipid accumulation causes
hepatic lipotoxicity resulting in the excessive production of saturated and monounsaturated
free fatty acids (FFAs) [40, 46, 56]. These FFAs undergo β-oxidation leading to formation of
reactive oxygen species that will further induce mitochondrial damage, endothelial reticulum
stress, and gene transcription promoting inflammatory cell signaling pathways.
As a result of the hepatic insulin resistance an increase in the liver of free fatty acids (FFAs) is
observed, mainly due to dysregulation of the lipolysis and lipogenesis balance, resulting
lipotoxicity that will determine chronic damage to hepatic tissue [51]. But, lipotoxicity is not
due only as consequence of the excessive accumulation of FFAs in the liver, and the modifi-
cation of lipid composition is another contributor to lipotoxicity, and recent studies are
aimed at searching for specific metabolic changes as potential signatures of development of
HCC in patients with NAFLD [57]. For example, some studies show that, during natural
history of progression from normal liver to NAFLD or NASH, the ratio of polyunsaturated
fatty acids (PUFAs) is increased in NASH, and phosphatidylcholine (PC) levels are reduced
in both NAFLD and NASH, and based on these observations, it has been suggested that the
LPA signaling axis may be one of the mechanism that is connecting hepatic steatosis to HCC
[5861].
3.4. Microbiota: Intestinal flora dysregulation
The basis for the ongoing interest on the role of gut microbiota in progression of NAFLD was
the observation of fatal NASH that occurred in patients undergoing jejunoileal bypass in
bariatric surgery and the reversal after metronidazol therapy [62]. There are several evidences
that demonstrate a high prevalence of small intestinal bacterial overgrowth in patients with
NAFLD/NASH and that also demonstrate the role of microbiota modifications in the develop-
ment of NAFLD and NASH [45]. Specific microflora changes may play an important role in
progression of hepatic steatosis, especially in obese patients. In patients with NAFLD and
NASH was observed a difference in microbiota composition compared with healthy popula-
tion [63, 64]. The mechanisms implicated in the progression of gut microbiota-related NAFLD
and NASH and HCC are: alteration of intestine permeability, persistent activation of innate
immune system with consequent chronic inflammation, changes in bile acid metabolism [65].
Patients with NAFLD or NASH show increased levels of lipopolysaccharides (LPS), a known
innate immune system activator, on serum confirming the inflammatory state associated with
this conditions and alteration in gut permeability with disruption of intercellular tight junc-
tions observed in patients with NAFLD can contribute directly to lipopolysaccharides action to
the liver [65, 66].
All these findings were confirmed in human study wherein increased LPS-binding protein
(LBP) levels were observed in obese patients with NAFLD and even more in obese patients
with NASH, correlating with liver TNFα increased expression [67].
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All these mechanisms show how changes in the microbiota, in combination with loss of innate
immune sensors, may induce metabolic liver disorders.
Gut microbiota also influences bile acid metabolisms mainly through the stimulation of the
bile-acid-activated nuclear receptor and also by interacting with farnesoid X receptor (FXR)
which induce excretion of bile acids from the liver and production of antimicrobial peptides
[65].
4. Conclusions
Although significant progress has been made in NAFLD/NASH related HCC, many issues still
remain to be resolved. With the prevalence of HCV declining in the last years, the incidence of
NAFLD/NASH is expected to account for a greater proportion of HCC incidence in the near
future due to the growing epidemic of obesity, diabetes and metabolic syndrome, known as
independent metabolic risk factors for development of HCC. The annual incidence rate of
HCC developed in patients with NASH-related cirrhosis is not yet clearly established and
recent evidence show that a significant number of patients with NAFLD or NASH progress to
HCC in the absence of hepatic cirrhosis. NAFLD/NASH-related cirrhotic patients receive
significantly less surveillance for HCC than those with HCV-related cirrhosis, in contrast to
epidemiological data and this represents an important public health problem. Also dysbiosis
play an important role in progression of liver disease via changes in bile acids metabolism and
dysregulation of intestinal barrier.
In conclusion, metabolic syndrome comprising of obesity, type 2 diabetes, dyslipidemia,
hypertension, is related with an increased risk for development of HCC. NAFLD considered
the liver manifestation of metabolic syndrome is an important factor implicated in progression
to HCC. Also alteration in gut microbiota seems to be connected with HCC occurrence but
many questions still remain to be answered.
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